Techbio Tailor Bio has published a pivotal study demonstrating the power of chromosomal instability (CIN) signatures to predict resistance to widely used chemotherapy drugs across multiple cancer types. 

The study, carried out in collaboration with the University of Cambridge and the Spanish National Cancer Research Centre, used Tailor Bio’s CIN biomarker platform. 

The platform identified patients unlikely to respond to platinum-, taxane-, and anthracycline-based treatments using a single genomic test, including from blood-derived DNA.  

The analysis, based on real-world clinical data from 840 patients with ovarian, breast, prostate, and sarcoma cancers, revealed that patients predicted to be resistant were up to seven times more likely to experience treatment failure. 

Despite widespread use, most chemotherapy regimens remain untargeted, lacking precision biomarkers to guide their use. This often results in patients receiving toxic therapies with no clinical benefit.  

Tailor Bio hopes its platform can address this unmet need by leveraging CIN signatures to personalise chemotherapy decisions and, longer term, guide development of novel drugs targeting CIN-driven cancers. 

CIN, a hallmark of 80% of human cancers, is associated with treatment resistance, tumour aggressiveness, and poor prognosis 

“Our mission is to personalise cancer care across the spectrum—from legacy chemotherapies to next-generation targeted therapies,” said Dr Jason Yip, Chief Executive Officer, Tailor Bio. “Our platform not only helps clinicians make better treatment decisions today, but also accelerates the development of tomorrow’s cancer drugs by enabling patient selection based on CIN biology.” 

Tailor Bio was spun out of the Cancer Research UK Cambridge Institute following Dr Macintyre’s discovery of CIN signature-drug response correlations in ovarian cancer organoids.  

Alongside improving chemotherapy treatment, the company is using its platform to develop new targeted therapies specifically for cancers with CIN.

Diana Spencer, Senior Digital Content Editor, DDW